Clinical Trials
504
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (351 trials with phase data)• Click on a phase to view related trials
6 Weeks Right-Amygdala TIS for Depression
- Conditions
- Major Depressive Disorder (MDD)
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT07059143
- Locations
- 🇨🇳
The Affiliated Brain Hospital Of Guangzhou Medical University, Guangdong, China
🇨🇳Ruijin Hospital, Shanghai, China
🇨🇳Anding Hospital (Mental Health Center of Tianjin Medical University), Tianjin, China
Investigating the Mechanisms of Welwalk Robot in Restoring Motor Function of the Lower Extremities in Stroke Patients
- Conditions
- StrokeWalking Impairment
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT07057700
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University, School of medicine,, Shanghai, Shanghai, China
Individualized rTMS Synchronized Task Training for Closed-loop Neuromodulation of Post-stroke Motor Dysfunction
- Conditions
- Upper Extremity Dysfunction After the Stroke
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT07049211
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University, School of medicine, Shanghai, Shanghai, China
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
- Conditions
- Multiple System Atrophy
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT07036939
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer (CRC)Tumor Infiltrating LymphocytesPD-1
- Interventions
- Biological: transfusion of 5×10^8 PD-1 knockout TILs per kg body weightBiological: transfusion of 1×10^9 PD-1 edited TILs per kg body weightBiological: transfusion of 2×10^9 PD-1 edited TILs per kg body weightBiological: transfusion of maximum dose without side effects among group A, B and C
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT07035002
- Locations
- 🇨🇳
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, None Selected, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next
News
Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial
Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.
CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease
CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.